



Symic Bio Announces First Patient Enrolled in Osteoarthritis Phase 2b Study

SAN FRANCISCO, March 1, 2020 – Symbic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the first patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symbic Bio's DMOAD (disease-modifying OA drug) candidate, SB-061 vs. placebo control.

MODIFY3 will enroll up to 300 patients who will each undergo 3 intra-articular injections of SB-061 or saline over 6 months. The primary endpoint will be pain over 6 months. Secondary endpoints include structural investigation of disease-modification using MRI over 12 months. "We are excited to be leading this trial," said Professor Morten Karsdal, PhD, CEO of Nordic Bio in Denmark. "Osteoarthritis therapeutics, particularly disease-modifying candidates, aim to address a huge unmet need for patients suffering from this debilitating disease. SB-061 is one of the most advanced drugs in development that has both pain and disease-modifying potential."

Further, Symbic Bio (USA) has announced that it has partnered SB-061 with an investor syndicate led by DDF (Den Danske Forskningsfond) of Denmark. Symbic Bio (Denmark) will be funded by DDF and other syndicate investors, and will taken responsibility for the development of SB-061 going forward.

About Nordic Bio

Nordic Bioscience is dedicated to preclinical and clinical drug development. They have more than 25 years' experience in biomarker development and clinical trials and have extensive expertise in rheumatology and fibrosis. By combining their experience in preclinical and clinical research, they are able to help provide faster and smarter detection of signals of the potential clinical viability of drug candidates. As a privately owned, specialized company, Nordic Bio is able to make decisions swiftly, leverage cross-functional synergies and quickly adapt the organization to best accommodate current and future needs. For additional information please visit the company's website at www.nordicbioscience.com

About Symbic Bio

Symbic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symbic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting peripheral vascular disease. For additional information please visit the company's website at www.symbic.bio

Investor Contact

ir@symic.bio

Media Contacts

pr@symic.bio